<code id='9750E130EC'></code><style id='9750E130EC'></style>
    • <acronym id='9750E130EC'></acronym>
      <center id='9750E130EC'><center id='9750E130EC'><tfoot id='9750E130EC'></tfoot></center><abbr id='9750E130EC'><dir id='9750E130EC'><tfoot id='9750E130EC'></tfoot><noframes id='9750E130EC'>

    • <optgroup id='9750E130EC'><strike id='9750E130EC'><sup id='9750E130EC'></sup></strike><code id='9750E130EC'></code></optgroup>
        1. <b id='9750E130EC'><label id='9750E130EC'><select id='9750E130EC'><dt id='9750E130EC'><span id='9750E130EC'></span></dt></select></label></b><u id='9750E130EC'></u>
          <i id='9750E130EC'><strike id='9750E130EC'><tt id='9750E130EC'><pre id='9750E130EC'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:fashion    - browse:2667
          Darron Cummings/AP

          Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

          The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

          advertisement

          Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia